NCT01556165

Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

Randomised, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose Study of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 130 (actual)
• Sponsor: H. Lundbeck A/S · Industry
• Sex: All
• Age: 35 Years
• Healthy volunteers: Not accepted

Summary

Rasagiline has been developed for the treatment of Parkinson's Disease (PD), as monotherapy in early PD patients not treated with levodopa, and as adjunct therapy to levodopa in levodopa-treated PD patients with motor fluctuations. The rationale for conducting this study is to evaluate the efficacy, tolerability, and safety of rasagiline compared to placebo in Chinese PD patients not treated with levodopa.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	rasagiline	1 mg/day, tablets, once daily, orally
DRUG	placebo	tablets, once daily, orally

Timeline

• Start date: 2012-04-01
• Primary completion: 2013-12-01
• First posted: 2012-03-16
• Last updated: 2014-12-23
• Results posted: 2014-12-23

Locations

15 sites across 1 country: China